Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Implementation Study of Long-acting Injectable Cabotegravir (CAB-LA) for HIV Pre-Exposure Prophylaxis (PrEP) Among Young MSM, Non-binary and Transgender Persons (The ImPrEP CAB Study)

Trial Profile

An Implementation Study of Long-acting Injectable Cabotegravir (CAB-LA) for HIV Pre-Exposure Prophylaxis (PrEP) Among Young MSM, Non-binary and Transgender Persons (The ImPrEP CAB Study)

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabotegravir (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms ImPrepCab; The ImPrEP CAB Study

Most Recent Events

  • 12 Mar 2025 According to a ViiV Healthcare media release, data from this study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025),
  • 12 Mar 2025 Results presented in the ViiV Healthcare Media Release
  • 06 Mar 2024 Results assessing the accuracy of indirect PrEP adherence measures with drug concentrations in dried blood spots (DBS) among YMSM and TGW enrolled in the ImPrEP study, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top